Business description: StemRIM

StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.

Number of employees: 48

Executive Committee: StemRIM

Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 01/10/2022
Chief Executive Officer 58 25/10/2023
Chief Administrative Officer - -
President 56 01/04/2010

Composition of the Board of Directors: StemRIM

Director TitleAgeSince
Chairman 66 01/09/2026
Director/Board Member 58 01/03/2019
Director/Board Member 54 01/10/2019
Director/Board Member 50 14/10/2020
Director/Board Member 59 28/10/2026

Shareholders: StemRIM

NameStocks%Valuation
15.92 %
9,980,000 15.92 % 9 M ¥
8.615 %
5,400,000 8.615 % 5 M ¥
7.418 %
4,650,000 7.418 % 4 M ¥
5.392 %
3,380,000 5.392 % 3 M ¥
5.172 %
3,241,900 5.172 % 3 M ¥

Holdings: StemRIM

NameStocks%Valuation
1000% 88 $

Company details: StemRIM

StemRIM, Inc.

Saito Bio Incubator, 3/F

567-0085, Osaka

+

http://stemrim.com
address StemRIM(4599)

Biopharmaceuticals

Change 5-day change 1-year change 3-year change Capi.($)
-1.59%+4.20%-55.23%-81.87% 49.59M
-2.32%-3.79%+34.24%+133.69% 1,232B
-2.15%-2.75%+36.35%+82.05% 656B
-2.33%-3.04%+22.29%+106.80% 506B
-0.81%-1.50%+29.08%+68.84% 382B
-3.90%-6.39%+42.88%+35.41% 340B
-2.92%-4.87%+24.91%+51.50% 294B
-1.55%-3.42%-1.04%+33.13% 278B
-3.07%-5.17%+29.04%+67.26% 240B
-0.75%-0.44%+32.87%+123.96% 210B
Average -0.93%-1.48%+19.54%+62.08% 414B
Weighted average by Cap. -0.74%-2.67%+29.94%+91.20%
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - StemRIM